Citadel Advisors’s Global Cord Blood Corporation CO Stock Holding History

Citadel Advisors’s Portfolio CO Stock Details CO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,100	Closed	-$18.2K	–	15793
2023 Q1	$18.2K	Sell	6,100 -1,600	-21%	-$4.78K	﹤0.01%	13132
2022 Q4	$23K	Sell	7,700 -5,100	-40%	-$15.2K	﹤0.01%	13030
2022 Q3	$38K	Buy	12,800 +700	+6%	+$1.72K	﹤0.01%	11791
2022 Q2	$36K	Sell	12,100 -6,600	-35%	-$20.5K	﹤0.01%	12138
2022 Q1	$72K	Buy	+18,700	New	+$77.6K	﹤0.01%	12560
2021 Q2	–	Sell	-10,900	Closed	-$49K	–	15020
2021 Q1	$49K	Buy	+10,900	New	+$47.3K	﹤0.01%	12915

Other funds holding CO

Natixis Advisors Boston, Massachusetts $71.9B AUM 28.03% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UMB Bank Kansas City, Missouri $7.16B AUM 20.88% 1-Year Est. Return

Operose Advisors Milwaukee, Wisconsin $431M AUM 20.45% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Citadel Advisors's CO Position: Q2 2023 in Review

Citadel Advisors sold out of Global Cord Blood Corporation (CO) in Q2 2023, closing a stake of 10,800 shares — an estimated $32.3K sold.

Citadel Advisors first reported a position in CO in Q4 2015 and held it in 22 quarters. The position peaked at $905K in Q1 2018. 6 funds tracked by Wall St. Rank hold CO as of Q2 2023.

Citadel Advisors reported no remaining Global Cord Blood Corporation position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 10,800 Global Cord Blood Corporation shares in Q2 2023, an estimated $32.3K.
Citadel Advisors first reported a position in Global Cord Blood Corporation in Q4 2015 and held it in 22 quarters.
Citadel Advisors's Global Cord Blood Corporation position peaked at $905K in Q1 2018.
6 funds tracked by Wall St. Rank held Global Cord Blood Corporation as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.